Advertisement
Screener

Biofrontera Inc. (BFRI) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

Biofrontera Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Biofrontera Inc. (BFRI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 100.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-13

  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 100.00%.
  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 100.00%.
  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 70.00%, a 27.27% increase year-over-year.
  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 55.00%.
  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 95.00%, a 5.00% decline from fiscal 2024.
  • Biofrontera Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 100.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2026-06-30100.00%
10-Q · filed 2026-08-13
2026-03-31100.00%
10-Q · filed 2026-05-14
2025-12-3195.00%
10-K · filed 2026-03-19
2025-09-3095.00%
10-Q · filed 2025-11-12
2024-12-31100.00%
10-K · filed 2026-03-19
2024-09-30100.00%
10-Q · filed 2024-11-14
2023-03-3170.00%
10-Q · filed 2023-05-12
2022-03-3155.00%
10-Q · filed 2023-05-12
2022-03-0255.00%
10-Q · filed 2022-05-13
2021-12-3155.00%
8-K · filed 2023-10-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Rocket One Inc. (RKTO)United States$0.019B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Korsana Biosciences, Inc. (CYCN)United States$0.016B